EFFECTS OF OBESITY ON THE SERUM BMP15, GDF9, AND KISSPEPTIN CONCENTRATIONS IN WOMEN OF REPRODUCTIVE AGE
OBESITY ON THE SERUM BMP15, GDF9, AND KISSPEPTIN
Abstract
Background: As BMP15, GDF9, and kisspeptin all play critical roles in folliculogenesis and fertilization, investigating the possible relationship between obesity and these three factors could prove crucial in relation to understanding the role of obesity in infertility. Thus, the present study sought to determine the effects of obesity on the serum BMP15, GDF9, and kisspeptin concentrations in women of reproductive age.
Methods: Ninety female participants were equally divided into three groups: class-1 obese (n=30), class-2 obese (n=30), and normal weight (control; n=30). The participants’ serum BMP15, GDF9, and AMH concentrations were measured. Moreover, the serum kisspeptin concentrations were evaluated in the class-1 obese and control groups by means the enzyme-linked immunosorbent assay (ELISA) method while the participants were in the menstrual period.
Results: The serum BMP15 and kisspeptin concentrations were found to be much higher in the control group than in both obese groups (p=0.001 and p=0.01, respectively). While the GDF9 concentration exhibited statistically significantly positive correlation with age, the BMP15 concentration exhibited positive correlation with both the kisspeptin and LH concentrations in the control group. In addition, positive correlation was identified between the BMP15 concentration and both age and the glucose level, as well as negative correlation with the insulin level, in both the obese groups.
Conclusions: Obesity appears to reduce the serum BMP15 and kisspeptin concentrations in obese women of reproductive age. This reduction may represent a milestone in terms of reproductive dysfunction, and it may be used to predict the success of infertility treatment in obese women.
References
[2] Bulut Arikan F. TRPV2 Polymorphisms Change the Risk of Type 2 Diabetes - Hashimoto Thyroiditis Comorbidity. Acta Endo (Buc) 2020;16:15–21. https://doi.org/10.4183/aeb.2020.15.
[3] Aksoy A, Selen H, Ozdemir FA, Bulut Arıkan F. Association of physical activity and obesity status for individuals between the ages of 18-30 via bioelectrical impedance analysis device and metabolic holter measurements. Progress in Nutrition 2018;19. https://doi.org/10.23751/pn.v19i4.5602.
[4] Broughton DE, Moley KH. Obesity and female infertility: potential mediators of obesity’s impact. Fertility and Sterility 2017;107:840–7. https://doi.org/10.1016/j.fertnstert.2017.01.017.
[5] Gesink Law DC, Maclehose RF, Longnecker MP. Obesity and time to pregnancy. Human Reproduction 2006;22:414–20. https://doi.org/10.1093/humrep/del400.
[6] Ml R, M C, Cr S, Dm M, Tm B, Ma C, et al. Obesity Modulates Inflammation and Lipid Metabolism Oocyte Gene Expression: A Single-Cell Transcriptome Perspective. J Clin Endocrinol Metab 2017;102:2029–38. https://doi.org/10.1210/jc.2016-3524.
[7] Shah DK, Missmer SA, Berry KF, Racowsky C, Ginsburg ES. Effect of Obesity on Oocyte and Embryo Quality in Women Undergoing In Vitro Fertilization. Obstetrics & Gynecology 2011;118:63–70. https://doi.org/10.1097/AOG.0b013e31821fd360.
[8] Wise LA, Rothman KJ, Mikkelsen EM, Sorensen HT, Riis A, Hatch EE. An internet-based prospective study of body size and time-to-pregnancy. Human Reproduction 2010;25:253–64. https://doi.org/10.1093/humrep/dep360.
[9] Provost MP, Acharya KS, Acharya CR, Yeh JS, Steward RG, Eaton JL, et al. Pregnancy outcomes decline with increasing body mass index: analysis of 239,127 fresh autologous in vitro fertilization cycles from the 2008–2010 Society for Assisted Reproductive Technology registry. Fertility and Sterility 2016;105:663–9. https://doi.org/10.1016/j.fertnstert.2015.11.008.
[10] Dube JL, Wang P, Elvin J, Lyons KM, Celeste AJ, Matzuk MM. The Bone Morphogenetic Protein 15 Gene Is X-Linked and Expressed in Oocytes. Molecular Endocrinology 1998;12:1809–17. https://doi.org/10.1210/mend.12.12.0206.
[11] Belli M, Shimasaki S. Molecular Aspects and Clinical Relevance of GDF9 and BMP15 in Ovarian Function. Vitamins and Hormones, vol. 107, Elsevier; 2018, p. 317–48. https://doi.org/10.1016/bs.vh.2017.12.003.
[12] Bedenk J, Vrtačnik-Bokal E, Virant-Klun I. The role of anti-Müllerian hormone (AMH) in ovarian disease and infertility. J Assist Reprod Genet 2020;37:89–100. https://doi.org/10.1007/s10815-019-01622-7.
[13] Voorhuis M, Broekmans FJ, Fauser BCJM, Onland-Moret NC, van der Schouw YT. Genes Involved in Initial Follicle Recruitment May Be Associated with Age at Menopause. The Journal of Clinical Endocrinology & Metabolism 2011;96:E473–9. https://doi.org/10.1210/jc.2010-1799.
[14] Gottsch ML, Cunningham MJ, Smith JT, Popa SM, Acohido BV, Crowley WF, et al. A Role for Kisspeptins in the Regulation of Gonadotropin Secretion in the Mouse. Endocrinology 2004;145:4073–7. https://doi.org/10.1210/en.2004-0431.
[15] Saadeldin IM, Koo OJ, Kang JT, Kwon DK, Park SJ, Kim SJ, et al. Paradoxical effects of kisspeptin: it enhances oocyte in vitro maturation but has an adverse impact on hatched blastocysts during in vitro culture. Reprod Fertil Dev 2012;24:656–68. https://doi.org/10.1071/RD11118.
[16] Tolson KP, Garcia C, Yen S, Simonds S, Stefanidis A, Lawrence A, et al. Impaired kisspeptin signaling decreases metabolism and promotes glucose intolerance and obesity. J Clin Invest 2014;124:3075–9. https://doi.org/10.1172/JCI71075.
[17] Su Y-Q, Wu X, O’Brien MJ, Pendola FL, Denegre JN, Matzuk MM, et al. Synergistic roles of BMP15 and GDF9 in the development and function of the oocyte-cumulus cell complex in mice: genetic evidence for an oocyte-granulosa cell regulatory loop. Dev Biol 2004;276:64–73. https://doi.org/10.1016/j.ydbio.2004.08.020.
[18] Patiño LC, Walton KL, Mueller TD, Johnson KE, Stocker W, Richani D, et al. BMP15 Mutations Associated With Primary Ovarian Insufficiency Reduce Expression, Activity, or Synergy With GDF9. J Clin Endocrinol Metab 2017;102:1009–19. https://doi.org/10.1210/jc.2016-3503.
[19] Persani L, Rossetti R, Di Pasquale E, Cacciatore C, Fabre S. The fundamental role of bone morphogenetic protein 15 in ovarian function and its involvement in female fertility disorders. Human Reproduction Update 2014;20:869–83. https://doi.org/10.1093/humupd/dmu036.
[20] Riepsamen AH, Chan K, Lien S, Sweeten P, Donoghoe MW, Walker G, et al. Serum Concentrations of Oocyte-Secreted Factors BMP15 and GDF9 During IVF and in Women With Reproductive Pathologies. Endocrinology 2019;160:2298–313. https://doi.org/10.1210/en.2019-00264.
[21] Arifin Z, Sumapradja K, Anggraeni U, Muna N, Wiweko B. THE RELATIONSHIP BETWEEN GDF-9 AND BMP-15 SERUM AND FOLLICULAR FLUID AND THE QUALITY OF OOCYTES IN WOMEN WHO UNDERGO AN IVF CYCLE. International Journal of Applied Pharmaceutics 2020:22–7. https://doi.org/10.22159/ijap.2020.v12s3.39463.
[22] Padilla SL, Perez JG, Ben-Hamo M, Johnson CW, Sanchez R, Bussi I, et al. Kisspeptin Neurons in the Arcuate Nucleus of the Hypothalamus Orchestrate Circadian Rhythms and Metabolism. Curr Biol 2019;29:592-604.e4. https://doi.org/10.1016/j.cub.2019.01.022.
[23] Tolson KP, Marooki N, Wolfe A, Smith JT, Kauffman AS. Cre/lox generation of a novel whole-body Kiss1r KO mouse line recapitulates a hypogonadal, obese, and metabolically-impaired phenotype. Mol Cell Endocrinol 2019;498:110559. https://doi.org/10.1016/j.mce.2019.110559.
[24] Rafique N, Latif R. Serum kisspeptin levels in normal and overweight Saudi females and its relation with anthropometric indices. Ann Saudi Med 2015;35:157–60. https://doi.org/10.5144/0256-4947.2015.157.
[25] Kołodziejski PA, Pruszyńska-Oszmałek E, Korek E, Sassek M, Szczepankiewicz D, Kaczmarek P, et al. Serum Levels of Spexin and Kisspeptin Negatively Correlate With Obesity and Insulin Resistance in Women. Physiol Res 2018:45–56. https://doi.org/10.33549/physiolres.933467.
Copyright (c) 2022 Funda BULUT ARIKAN, Nevin SAGSOZ
This work is licensed under a Creative Commons Attribution 4.0 International License.
The published articles will be distributed under the Creative Commons Attribution 4.0 International License (CC BY). It is allowed to copy and redistribute the material in any medium or format, and remix, transform, and build upon it for any purpose, even commercially, as long as appropriate credit is given to the original author(s), a link to the license is provided and it is indicated if changes were made. Users are required to provide full bibliographic description of the original publication (authors, article title, journal title, volume, issue, pages), as well as its DOI code. In electronic publishing, users are also required to link the content with both the original article published in Journal of Medical Biochemistry and the licence used.
Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.